Predicate Research Report · generated 2026-08-23 · Print / save as PDF · Save to account
PAM · Predicate Candidate Screening
7 FDA 510(k) clearances under this product code; the 50 most recent screened below.
206 daysmedian FDA review time
249 days90th percentile
7clearances measured
| K-number | Device | Applicant | Decided | Review days | Recalls (K-match) |
|---|---|---|---|---|---|
| K254194 | QIAstat-Dx BCID GPF Plus AMR Panel | QIAGEN GmbH | 2026-08-06 | 226 | 0 |
| K243490 | LIAISON PLEX Gram-Positive Blood Culture Assay | Luminex Corporation | 2025-06-06 | 206 | 0 |
| K181663 | ePlex Blood Culture Identification Panel - Gram Positive (BC | Genmark Diagnostics, Incorporated | 2018-12-20 | 178 | 0 |
| K163390 | iC-GPC Assay TM for use on the iC-SystemTM | Icubate, Inc. | 2017-08-08 | 249 | 0 |
| K152470 | Great Basin Staph ID/R Blood Culture Panel | Great Basin Scientific, Inc. | 2016-03-25 | 207 | 1 |
| K122514 | VERIGENE GRAM-POSITIVE BLOOD CULTURE (GC-GP) NUCLEIC ACID TE | Nanosphere, Inc. | 2012-09-19 | 33 | 6 |
| DEN120014 | VERIGENE GRAM POSITIVE BLOOD CULTURE NUCLEIC ACID TEST (BC-G | Nanosphere, Inc. | 2012-06-26 | 11 | 0 |
Methodology
Recall counts reflect FDA recall records explicitly referencing each K-number; FDA links recalls to K-numbers inconsistently, so 0 means "none found in FDA records," not "never recalled." Data: FDA openFDA, refreshed weekly. Verify decisions of consequence against the primary source. Full candidate set and CSV export: atlasbyauro.com.
Prepared with Atlas
Predicate research, review-time statistics and recall monitoring for 510(k) teams: atlasbyauro.com/fda